Why a consensus conference on hormone replacement therapy and the cardiovascular system?
Authors:
- G. BenagianoGBG. Benagiano
- M. FarrisMFM. Farris
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- UK high court dismisses risk of VTE in “pill” test caseThe Lancet, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studiesThe Lancet, 1996
- Comparative Pharmacology of Newer ProgestogensDrugs, 1996
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Post-marketing evaluation of fertility-regulating drugs as viewed by the pharmaceutical industryHuman Reproduction, 1987
- BREAST CANCER IN YOUNG WOMEN AND USE OF ORAL CONTRACEPTIVES: POSSIBLE MODIFYING EFFECT OF FORMULATION AND AGE AT USEThe Lancet, 1983
- Oral contraceptives and breast cancer: Final report of an epidemiological studyBritish Journal of Cancer, 1983
- THROMBOEMBOLISM AND ORAL CONTRACEPTIVERS: AN EPIDEMIOLOGIC CASE-CONTROL STUDY12American Journal of Epidemiology, 1969